Aptamer Group has launched its biomarker discovery service, offering researchers in pharmaceutical, biotechnology, and diagnostic development a new approach to identify and validate new disease markers. 

The service integrates Aptamer’s Optimer technology with proteomic analysis to provide an unbiased, high-throughput approach to biomarker identification.  

This methodology simultaneously identifies biomarkers and generates corresponding affinity ligands, as aptamers. 

The platform utilises Optimers, which are short, synthetic oligonucleotide molecules with enhanced stability and binding specificity, to differentiate between healthy and diseased cell or tissue samples.  

Through subsequent proteomic analysis, precise identification of the molecular biomarkers can be achieved, delivering both validated biomarkers and immediately applicable aptamers as affinity ligands, or the potential to pursue the biomarkers with alternative modalities, such as antibodies. 

Biomarkers can also be identified that support specific strategies, such as receptor-mediated endocytosis for drug delivery approaches.  

The company demonstrated its approach through the internal identification of biomarkers for fibrotic liver targeting. 

Dr Arron Tolley, Chief Executive Officer of Aptamer Group, commented: “Our biomarker discovery service addresses a fundamental challenge in life sciences research, which is the need for faster, more efficient identification of clinically relevant molecular targets. By combining our Optimer libraries with proteomic capabilities, we can deliver validated biomarkers alongside functional binding tools, significantly accelerating the translation from discovery to application. The strong interest we’ve received from pharmaceutical and biotechnology partners demonstrates the value of this integrated approach.” 

Read the DDW interview with Arron Tolley. 

Diana Turner, Senior Digital Content Editor, DDW